Dilek Yağcı Çağlayık

Dilek Yağcı Çağlayık

Auto-generated profile, based on publicly available information

Dilek Yağcı Çağlayık

Marmara University Faculty of Medicine

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Journal of Clinical Virology
Verified
Journal Article
Closed access
IHImran Hasanoglu
Imran Hasanoglu
RGRahmet Guner
Rahmet Guner
ACAhmet Carhan
Ahmet Carhan
ZTZeliha Kocak Tufan
Zeliha Kocak Tufan
DYDilek Yagci-Caglayik
Dilek Yagci-Caglayik
MTMehmet A. Tasyaran
Mehmet A. Tasyaran

12 March 2020 in Eurosurveillance
Verified
Journal Article
Open access
DYDilek Yagci-Caglayik
Dilek Yagci-Caglayik
BKBircan Kayaaslan
Bircan Kayaaslan
DYDerya Yapar
Derya Yapar
AKAysel Kocagul-Celikbas
Aysel Kocagul-Celikbas
AOAslinur Ozkaya-Parlakay
Aslinur Ozkaya-Parlakay
AOAykut Ozkul
Aykut Ozkul
Introduction: Crimean-Congo haemorrhagic fever (CCHF) is a tick-borne disease in Africa, Asia, the Balkan peninsula, the south-east of Europe and the Middle East, with mortality rates of 3–30%. Transmission can also occur through contact with infected animals or humans. Aim: This observational, prospective case series aimed to investigate detectable viral genomic RNA in whole-body fluids and antibody dynamics in consecutive daily samples of patients diagnosed with CCHF until discharge from hospital. Methods: We tested 18 patients and 824 swabs and sera with RT-PCR and 125 serum samples serologically. Results: The longest duration until clearance of viral RNA was 18 days from serum collection and 18, 15, 13, 19 and 17 days, respectively, from nasal, oral, genital (urethral or vaginal) and faecal swab, and urine. In seven patients, viral load decreased in serum at the same time as it increased in urine or persisted at the same logarithmic values. Despite clearance in serum, viral RNA was detected in faeces and genital swabs in two and three patients, respectively. Viral clearance from body fluids occurred earlier than from serum in eight patients on ribavirin treatment. The shortest seroconversion time was 3 days after symptom onset for IgM and IgG. Seroconversion of IgG occurred until Day 14 of symptoms. Conclusion: We report persistence of viral RNA in urine, faeces and genital swabs despite serum clearance. This may indicate a need for extending isolation precautions, re-evaluating discharge criteria and transmission risk after discharge, and considering oral swabs as a less invasive diagnostic alternative.

1 May 2015 in Journal of Clinical Virology
Verified
Journal Article
Closed access
MAMehmet ARASLI
Mehmet ARASLI
YOYasemin Ozsurekci
Yasemin Ozsurekci
NENazif Elaldi
Nazif Elaldi
AMAlexander McAuley
Alexander McAuley
EOEda Karadag Oncel
Eda Karadag Oncel
MCMehmet Ceyhan
Mehmet Ceyhan

1 July 2010
Verified
Journal Article
Closed access
SKSelçuk Kaya
Selçuk Kaya
GYGürdal Yılmaz
Gürdal Yılmaz
SESükrü Erensoy
Sükrü Erensoy
DÇDilek Yağçı Çağlayık
Dilek Yağçı Çağlayık
YUYavuz Uyar
Yavuz Uyar
IKIftihar Koksal
Iftihar Koksal

24 January 2013 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
YUYavuz Uyar
Yavuz Uyar
EAEray Aktaş
Eray Aktaş
DÇDilek Yağci Çağlayik
Dilek Yağci Çağlayik
Onder ErgonulOnder Ergonul
Onder Ergonul
AYAyşe YÜCE
Ayşe YÜCE
<%=header_description %> <%=header_description %> Yurt Dışı Kaynaklı Bir Dang Ateşi Olgusu ve Literatürün Gözden Geçirilmesi An Imported Dengue Fever Case in Turkey and Review of the Literature

10 March 2023 in AIDS Patient Care and STDs
Verified
Journal Article
Closed access
LALutfiye Nilsun Altunal
Lutfiye Nilsun Altunal
DCDilek Yagcı Caglayık
Dilek Yagcı Caglayık
AOAyse Serra Ozel
Ayse Serra Ozel
ETElif Tukenmez Tigen
Elif Tukenmez Tigen
USUluhan Sili
Uluhan Sili
VKVolkan Korten
Volkan Korten
People living with human immunodeficiency virus (PLWH), with the availability of modern antiretroviral drugs, have multiple comorbidities, which increase the risk of polypharmacy and potential drug-drug interactions (PDDIs). This is a particularly important issue for the aging population of PLWH. This study aims to review the prevalence and risk factors for PDDIs and polypharmacy in the era of HIV integrase inhibitors. A cross-sectional, two-center, prospective observational study was conducted on Turkish outpatients between October 2021 and April 2022. Polypharmacy was defined as the use of ≥5 non-HIV medications, excluding over-the-counter (OTC) drugs, and PDDIs were classified using the University of Liverpool HIV Drug Interaction Database (harmful/red flagged and potentially clinically relevant/amber flagged). The median age of the 502 PLWH included in the study was 42 ± 12.4 years and 86.1% were males. Most individuals (96.4%) were given integrase-based regimens (unboosted 68.7% and boosted 27.7%). In total, 30.7% of individuals were taking at least one OTC drug. The prevalence of polypharmacy was 6.8% (9.2% when OTC drugs were included). During the study period, the prevalence of PDDIs was 1.2% for red flag PDDIs and 16% for amber flag PDDIs. CD4+ T cell count >500 cells/mm3, number of comorbidities ≥3, comedication with drugs affecting blood and blood-forming organs, cardiovascular drugs, and vitamin/mineral supplements were associated with red flag or amber flag PDDIs. Drug interaction prevention is still important in HIV care. Individuals with multiple comorbidities should be closely monitored for non-HIV medications to prevent PDDIs.